Viridian Therapeutics CEO Steve Mahoney has announced the company’s readiness for a potential rivalry with Amgen’s Tepezza in treating thyroid eye disease. Following the release of new Phase 3 data, Viridian’s stock surged on Monday. The results highlight the therapeutic potential of Viridian’s treatment as a competitor to Amgen’s established medication, paving the way for future clinical trials and potential market presence.
Source: https://endpts.com/viridian-readies-for-tepezza-rivalry-with-new-phase-3-data-in-thyroid-eye-disease